You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Plasma-assisted atomic layer deposition of alumina and Parylene-C bi-layer encaps

    SBC: BLACKROCK MICROSYSTEMS, INC            Topic: NIBIB

    DESCRIPTION provided by applicant A range of neurological diseases are now being researched or treated using fully implantable electronic systems to either record or modulate brain activity in humans These implants are currently being protected using polymer coatings that envelop the implant and help keep body fluids away from the sensitive electronics Brain implants with complex three dimens ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Epoch Telemetry System for Long-Term Monitoring of Biopotentials

    SBC: EPITEL, INC.            Topic: 102

    DESCRIPTION provided by applicant Epoch Telemetry System for Long Term Monitoring of Biopotentials ABSTRACT Epochandquot is a wireless multi channel biopotential recording system designed for small animal translational research models of human disease developed in Phase I and II Obtaining long term continuous recordings from animal models of disease is a critical component of translational ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Corneal Endothelial Stem Cells for Treatment of Corneal Endothelial Dystrophies

    SBC: RASHMIVU LLC            Topic: N

    DESCRIPTION provided by applicant Corneal clouding caused by failure of the corneal endothelial deturgesence mechanism affects over million people in the US and well over million people worldwide It is the most common corneal disease and is historically a common cause of blindness Surgical treatment by corneal grafting has been successful when available but is limited by the availabili ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Single Therapy for Wet AMD & Geographic Atrophy

    SBC: Novelmed Therapeutics Inc            Topic: W

    DESCRIPTION provided by applicant Approximately of the total age related macular degeneration AMD patients have the Dry form Geographic atrophy GA is the advanced form of Dry AMD and is caused by the degeneration of the retinal epithelial cells While GA is less common than Wet AMD it is responsible for of legal blindness in the US There is currently no FDA approved treatment ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. New Approach to Phospholipidosis Prediction

    SBC: ECHELON BIOSCIENCES, INC.            Topic: FDA

    DESCRIPTION provided by applicant Drug safety is a major concern for pharmaceutical groups regulatory bodies basic researchers and particularly patients Safe and effective drugs maximize successful clinical outcomes and patient compliance This project will provide unique tools for detecting drugs that have potential to induce the dangerous outcome phospholipidosis early in the drug developm ...

    SBIR Phase II 2014 Department of Health and Human ServicesFood and Drug Administration
  6. Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

    SBC: THERATARGET, INC.            Topic: NCI

    DESCRIPTION provided by applicant The purpose of this Phase II STTR project is to develop a polymeric system for the combination delivery of two antineoplastic agents gemcitabine and paclitaxel Based on the successful results of the STTR Phase I award this Phase II proposal details the rationale and research plan for the synthesis and evaluation of in vivo efficacy of two novel macromolecula ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis

    SBC: Novelmed Therapeutics Inc            Topic: 400

    DESCRIPTION provided by applicant NovelMed intends to develop a humanized anti Bb antibody as a prophylactic treatment for inflammatory responses associated with hemodialysis During this procedure blood contacts the artificial surfaces of the dialyzer activating the alternative complement pathway AP AP activation causes cellular activation and production of inflammatory mediators with po ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. 3D Virtual Slide System for Creation and Analysis of Focusable Digital Slides

    SBC: MICROBRIGHTFIELD, LLC            Topic: 101

    DESCRIPTION provided by applicant This project aims to develop a novel system Biolucida AT which will greatly enhance the use of array tomography the state of the art method for investigating synaptic plasticity at the molecular level in human postmortem research and animal models of psychiatric neurological and childhood developmental disorders Synaptic transmission is essential for centr ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Cost-effective MHz rate Optical Coherence Tomography for biomedical applications

    SBC: WASATCH PHOTONICS, INC.            Topic: NIBIB

    DESCRIPTION provided by applicant During this SBIR Phase I project we propose to build and test in phantoms a prototype of an innovative cost effective Optical Coherence Tomography OCT system with a X increase in acquisition rate compared to commercially available systems Further development may add an additional X increased acquisition rate for a total of X Current market demand for ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Blocking a novel cytokine signaling pathway for the treatment of rheumatoid arthr

    SBC: NAVIGEN, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant In spite of remarkable progress in management of rheumatoid arthritis RA a devastating autoimmune disease that affects million Americans causing chronic inflammation of joints and surrounding tissues the gap of unmet needs in this therapeutic field remains wide open First of all almost of the patients do not respond adequately to the most advanced ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government